Warner-lambert Company

University of Michigan

The Rockefeller University

Alan Robert Saltiel

Alexander James Bridges

David Thomas Dudley

Haile Tecle

Stephen Douglas Barrett

Annette Marian Doherty

Hollis Showalter

Mel C Schroeder

Scott D Larsen

Charles Larry Bisgaier

Paul Leroy Creger

Donna Reynolds Cody

Sherrie Rae Tafuri

Elizabeth Ann Lunney

James Marino Hamby

David W Fry

Charles J Stankovic

Mark Stephen Plummer

James Leslie Mobley

Tomi Sawyer

Kimberly Suzanne Para

John J Tesmer

Josyula Venkata Prasad

Aurash B Shahripour

Xinmin Gan

John Andrew Printen

Matthew Jemail Brady

Stuart Decker

Stuart James Decker

Juswinder Singh

Hollis D Showalter

Shian-Huey Chiang

Carey Lumeng

Merlijn Bazuine

Provided herein is technology relating to deuterated amlexanox and particularly, but not exclusively, to compositions comprising deuterated amlexanox, methods of producing deuterated amlexanox, and uses of deuterated amlexanox.

Deuterated amlexanox

Provided herein are compositions and methods for the treatment of obesity and related disorders, including, but not limited to insulin resistance, diabetes, and hepatic steatosis. For example, in some embodiments, pharmaceutically acceptable compositions and methods are provided employing amlexanox, a derivative thereof, or a pharmaceutically acceptable salt thereof, alone or in combination with other agents and/or medical interventions, for the treatment, prevention, and management of such diseases and conditions.

Compositions and methods for the treatment of obesity and related disorders

Provided herein are amlexanox analogs and methods for the treatment and/or prevention of diabetes, impaired insulin signaling, obesity, or other related diseases and conditions therewith.

Amlexanox analogs

Provided herein is technology relating to deuterated amiexanox and particularly, but not exclusively, to compositions comprising deuterated amiexanox, methods of producing deuterated amiexanox, and uses of deuterated amiexanox. Provided herein are deuteratecl amiexanox compounds for the treatment of obesity, insulin resistance, diabetes, and steatosis. In addition, the deuterated compounds are anti-inflammatory antiallergic immunomodulators. e.g., for the treatment of diseases associated with inflammation. The deuterium kinetic isotope effect associated with placing deuterium at the site of metabolic derivatization slows metabolic derivatization and thus increases the lifetime of the active drug in vivo.

Phenylamino benzhydroxamic acid derivatives of the formula where R, R, R, R, R, and Rare hydrogen or substituent groups such as alkyl, and where Ris hydrogen or an organic radical, are potent inhibitors of MEK and, as such, are effective in treating cancer and other proliferative diseases such as psoriasis and restenosis.

4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors

Phenylamino benzoic acid, benzamides, and benzyl alcohol derivatives of the formula

2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives

Phenylamino benzhydroxamic acid derivatives of formula (I) where R , R , R , R , R , and R are hydrogen or substituent groups such as alkyl, and where R is hydrogen or an organic radical, are potent inhibitors of MEK and, as such, are effective in treating cancer and other proliferative diseases such as psoriasis and restenosis.

4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors

This invention provides a method of preventing or treating asthma by administering to a patient in need of treatment an effective amount of a selective MEK inhibitor, especially a phenyl amine of Formula I and II:

Treatment of asthma with MEK inhibitors

2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors

The present invention provides a method for treating or preventing septic shock. Specifically, the present invention provides a method of treating or preventing septic shock by administering to a patient a MEK inhibitor.

Method of treating or preventing septic shock by administering a MEK inhibitor

The present invention provides human and murine genomic and complementary DNA and the proteins that are encoded by the DNA, which is called &ldquo;Protein Targeting to Glycogen&rdquo;. Also provided is a method of increasing the amount of glycogen in a cell.

Protein targeting to glycogen

Compounds, compositions and methods for inhibiting the binding of

Growing community of inventors

Ann Arbor, MI, United States of America

Alan Robert Saltiel